AbbVie notches reprieve in antitrust case involving blood pressure med snagged in $63B Allergan megamerger

AbbVie and a slate of generic drugmakers won a reprieve against claims they conspired to stall generics of the blood pressure med Bystolic in the U.S.

A federal judge in New York tentatively scrapped two antitrust cases: one concerning direct purchasers like CVS and Walgreens and another with end payers as the plaintiffs. The drugmaker defendants were accused of delaying the market entry of copycats of the hypertension blockbuster, which AbbVie snagged by way of its $63 billion megamerger with Allergan.